How are Life Sciences M&A deals faring in a volatile macroeconomic climate?
The team at SRS Acquiom recently interviewed industry experts to learn more about the current state of Life Sciences M&A. In this article, we cover experts’ views on the pace of deals, regulatory impacts, and thoughts on what’s next for Life Sciences M&A. Inform your next negotiation with new perspectives:
- What’s weighing on Life Sciences M&A
- Who the buyers are
- Issues that matter when structuring deals and earnouts
- Information rights
- Impact of RWI
- And more
Gain fresh insights on life sciences M&A deals and put them to use on your next transaction.
Download the article above.
Casey is the managing director of SRS Acquiom’s professional services team and shareholder representation business. He also oversees thought leadership for the company, including development of SRS Acquiom’s industry-leading annual Deal Terms Study and the Claims, Life Sciences, and PPA Studies.
Before joining SRS Acquiom, Casey was a litigation & trial attorney at a San Francisco law firm. Casey represented Fortune 50 clients as well as SRS Acquiom and its clients, and took multiple cases to trial and appeal.
Casey received his B.S. from Arizona State University’s W. P. Carey School of Business, and his law degree from University of California, Berkeley. He is a licensed attorney in California.